2.06

1.44% -0.03

After Hours: 2.06

Lipocine Inc (LPCN)

Overview News Price History Financials Discussions Forecast Stock Split

Lipocine Inc stock is traded at $2.06, with a volume of 26,724. It is down -1.44% in the last 24 hours and down -0.96% over the past month. Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Previous Close:

$2.09

Open:

$2.07

24h Volume:

26,724

Relative Volume:

0.41

Market Cap:

$16.98M

Revenue:

$2.00M

Net Income/Loss:

$-11.43M

P/E Ratio:

-1.0526

EPS:

-1.957

Net Cash Flow:

$-10.05M

1W Performance:

+0.49%

1M Performance:

-0.96%

6M Performance:

-78.15%

1Y Performance:

-33.76%

1-Day Range:

$2.0501

$2.10

1-Week Range:

$2.04

$2.1349

52-Week Range:

$1.81

$12.37

Lipocine Inc Stock (LPCN) Company Profile

Name

Lipocine Inc

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

801 994 7383

Address

675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT

Employee

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

LPCN's Discussions on Twitter

Compare LPCN vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LPCN Lipocine Inc	2.06	17.23M	2.00M	-11.43M	-10.05M	-1.957
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Lipocine Inc Stock (LPCN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-06-26	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-24-21	Initiated	Cantor Fitzgerald	Overweight
Dec-10-20	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-12-18	Reiterated	H.C. Wainwright	Buy
Jan-11-18	Downgrade	Canaccord Genuity	Buy → Hold
Dec-08-17	Resumed	H.C. Wainwright	Buy
Oct-07-16	Initiated	H.C. Wainwright	Buy
Jul-22-15	Initiated	ROTH Capital	Buy
Jun-23-15	Initiated	Canaccord Genuity	Buy

View All

Lipocine Inc Stock (LPCN) Latest News

Aug 21, 2026

Lipocine (LPCN) adds Grissinger to pay panel at $7,500 a year - Stock Titan

Aug 21, 2026

Lipocine (LPCN) Q2 2026 Scorecard: EPS Comes in Above Forecast in Latest Trading; Price Reaction - vinanet.vn

Aug 21, 2026

Aug 18, 2026

Lipocine (LPCN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations in Latest Trading; Immediate Response: The Stock Ends Down 0.49% in the Current UpdateEarnings Preview - dars.gov.et

Aug 18, 2026

Aug 14, 2026

Lipocine Stock Price Forecast. Should You Buy LPCN? - StockInvest.us

Aug 14, 2026

Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan

Aug 14, 2026

Aug 12, 2026

LPCN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Revenue Remains Absent - Vinanet

Aug 12, 2026

Aug 10, 2026

Weekly Recap: Q2 revenue drop and Brilzio partner search - TradingView

Aug 10, 2026

LPCN Q2 2026 Earnings: Loss Narrower Than Expected, Shares Ease 1.41%Earnings Turnaround - vinanet.vn

Aug 10, 2026

Aug 07, 2026

Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options - Stock Titan

Aug 07, 2026